Press

Featured In

Biotheryx
July 17, 2024

Biotheryx Announces First Patient Dosed in Phase 1 Clinical Trial of BTX-9341, a First-in-Class, Dual Bifunctional Degrader of CDK4/6, as a Monotherapy and in Combination with Fulvestrant for HR+/HER2- Breast Cancer

Featured In

Parexel Podcast
June 28, 2024

Enabling Successful Sites Ep. 3: Taking the Complexity Out of Oncology Trials

Featured In

Pharmaceutical Executive
May 28, 2024

Finding Hope with Clinical Trials: Q&A with Nick Slack

Featured In

Labiotech.eu
May 22, 2024

The Undruggable Cancer Target: KRAS Inhibitors Move Ahead in the Clinic

Featured In

Santa Maria Local Health Unit
May 21, 2024

CEO of START Reinforces the Importance of the Santa Maria Phase 1 Oncology Trial Center

Featured In

HealthyWomen
May 20, 2024

The Connection Between Young Adults and Colon Cancer